MRI Contrast Agent Prototype Targets Cancers

University of Pennsylvania researchers have developed an experimental MRI contrast agent capable of targeting tumors, according to a report in the journal ACS Nano. Its coating, instead of targeting particular cancer receptors — which can be hit-or-miss and depend on the cancer — is attracted to the acidic environments in which tumors generally thrive.

The research was done by associate professor Andrew Tsourkas, PhD, and graduate student Samuel H. Crayton of the department of bioengineering in Penn’s School of Engineering and Applied Science.

Click here to read the full article